While direct comparisons to allo-HCT are lacking and follow-up is still limited, data from the major trials of CD19 CAR T therapy for relapsed/refractory DLBCL and real-world registries suggest durable CR rates of 30 to 40% with treatment-related toxicities that are more benign and relegated to the acute setting (Table 4). Here, CD19 is linked to diffuse large B-cell lymphoma.